|
Nov 6
|
Teva Pharmaceutical Industries (TEVA) Q3 2024 Earnings Call Transcript
|
|
Nov 6
|
Teva's Explosive Q3 Results: Pivot to Growth Strategy Shocks Investors with Record Revenue Surge
|
|
Nov 6
|
Teva Pharmaceutical Industries (TEVA) Reports Q3 Earnings: What Key Metrics Have to Say
|
|
Nov 6
|
Teva Pharmaceutical Flashes A Buy Signal On Upbeat Third-Quarter Report
|
|
Nov 6
|
Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS
|
|
Nov 5
|
What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?
|
|
Nov 4
|
Teva Pharmaceutical Industries (TEVA) Upgraded to Strong Buy: What Does It Mean for the Stock?
|
|
Nov 1
|
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
|
|
Nov 1
|
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well ...
|
|
Nov 1
|
Countdown to Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
|
|
Nov 1
|
EC fines Teva $502m over multiple sclerosis treatment Copaxone practices
|
|
Oct 31
|
Teva Fined Around $500 Million by EU Over MS Drug Competition Concerns
|
|
Oct 31
|
EU Commission fines Teva $500 million for trying to stop rival's multiple sclerosis drug
|
|
Oct 31
|
Teva Statement on European Commission Decision; Company to Appeal
|
|
Oct 11
|
Teva Pays $450M To Resolve Alleged Kickback, Price-Fixing Schemes
|
|
Oct 11
|
Update: Teva Pharmaceutical to Pay $450 Million to Settle Anti-Kickback Allegations
|
|
Oct 10
|
Teva Pharmaceuticals to Pay $450 Million to Settle Kickback Allegations
|
|
Oct 9
|
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2024 Earnings Call Highlights: Strong Revenue ...
|
|
Oct 8
|
Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
|
|
Jul 29
|
Hospital Business Recovery to Aid Haemonetics' (HAE) Q1 Earnings
|